Kura Oncology Inc. (KURA)
Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Kura Oncology, Inc. (KURA) Q4 2025 Earnings Call Transcript
Kura Oncology, Inc. (KURA) Q4 2025 Earnings Call Transcript
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates
Kura Oncology (KURA) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.22 per share a year ago.
Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline
Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy
Kura Oncology is upgraded from buy to strong buy, driven by a compelling valuation reset and robust cash position. Komzifti's FDA approval for relapsed/refractory NPM1-mutated AML is de-risked; the true equity upside lies in frontline AML expansion. Recent data show high remission rates and a favorable safety profile for Komzifti in frontline combinations, supporting the strategic thesis.
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data
Kura Oncology remains a Strong Buy, driven by Ziftomenib's differentiated safety profile and significant AML market potential. KURA's Ziftomenib avoids a QTc prolongation boxed warning, offering a potential safety edge over Syndax's Revuforj despite similar efficacy in R/R NPM1-mutated AML. Upcoming Phase 1b KOMET-007 data at ASH could shift market sentiment, with volatility expected as efficacy is compared to Syndax's robust results.
Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript
Kura Oncology, Inc. ( KURA ) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia November 13, 2025 12:30 PM EST Company Participants Greg Mann Troy Wilson - Chairman, CEO & President Mollie Leoni - Chief Medical Officer Brian Powl - Chief Commercial Officer Conference Call Participants Eunice Wang Daniel Bronder Jonathan Chang - Leerink Partners LLC, Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Erik Lavington - Mizuho Securities USA LLC, Research Division Jiale Song - Jefferies LLC, Research Division Bradley Canino - Guggenheim Securities, LLC, Research Division Philip Nadeau - TD Cowen, Research Division Jason Zemansky - BofA Securities, Research Division Etzer Darout - Barclays Bank PLC, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Operator At this time, I would like to welcome you to the Kura Oncology FDA approval conference call. [Operator Instructions] At this time, I would like to turn the call over to Greg Mann from Kura Oncology.
US FDA approves Kura Oncology's blood cancer therapy
The U.S. Food and Drug Administration has approved Kura Oncology's drug to treat a rare form of blood cancer that has returned or resisted initial therapy, the regulator said on Thursday.
Kura Oncology, Inc. (KURA) Q3 2025 Earnings Call Transcript
Kura Oncology, Inc. ( KURA ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Greg Mann Thomas Doyle - Senior Vice President of Finance & Accounting Troy Wilson - Chairman, CEO & President Mollie Leoni - Chief Medical Officer Brian Powl - Chief Commercial Officer Conference Call Participants Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Jason Zemansky - BofA Securities, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Salim Syed - Mizuho Securities USA LLC, Research Division Philip Nadeau - TD Cowen, Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Alexandre Bouilloux - Barclays Bank PLC, Research Division David Ruch Presentation Operator " Greg Mann " Thomas Doyle Senior Vice President of Finance & Accounting " Troy Wilson Chairman, CEO & President " Mollie Leoni Chief Medical Officer " Brian Powl Chief Commercial Officer " Unknown Analyst " Li Wang Watsek Cantor Fitzgerald & Co., Research Division " Cantor Fitzgerald & Co., Research Division Jason Zemansky BofA Securities, Research Division " BofA Securities, Research Division Yue-Wen Zhu LifeSci Capital, LLC, Research Division " LifeSci Capital, LLC, Research Division Operator Good day, everybody. My name is Danny, and I will be your conference operator today.
Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates
Kura Oncology (KURA) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.63 per share a year ago.
Kura Oncology's Ziftomenib Poised For Differentiation
Kura Oncology is reiterated as a strong buy, due to Ziftomenib's potential best-in-class safety profile in NPM1-mutated AML. Recent FDA approval of Syndax's Revuforj included a boxed warning for cardiac risks, highlighting Ziftomenib's potential safety advantage. KURA is well-capitalized, positioned for rapid commercialization post-expected FDA approval by November 2025, and could capture significant market share in a $3B+ market.
Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript
Kura Oncology, Inc. (NASDAQ:KURA ) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology October 18, 2025 1:30 PM EDT Company Participants Troy Wilson - Chairman, CEO & President Mollie Leoni - Chief Medical Officer Conference Call Participants Glenn J. Hanna Jonathan Chang - Leerink Partners LLC, Research Division Peter Green Reni Benjamin - Citizens JMP Securities, LLC, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Philip Nadeau - TD Cowen, Research Division Jason Zemansky - BofA Securities, Research Division Jiale Song - Jefferies LLC, Research Division Peter Lawson - Barclays Bank PLC, Research Division Presentation Operator Good day, and thank you for standing by.
